| 221 |
Management of Contrast Medium Safety |
Song Eun Park |
Apr. 19. 24 |
| 220 |
Management of PCI Complication |
Jae Jun Lee |
Apr. 19. 24 |
| 219 |
Management of EVAR and TEVAR |
Hwanhui Lee |
Apr. 19. 24 |
| 218 |
Following BEST-CLI and BASIL-2: How to “Best” Serve Critical Limb Threatening Ischemia? |
Lawrence A. Garcia |
Apr. 19. 24 |
| 217 |
Zilver PTX (Paclitaxel-Coated Stent): Transparency, Data, and Patient Safety |
Hiroyoshi Yokoi |
Apr. 19. 24 |
| 216 |
Expert Thoughts on Drug-Eluting Resorbable Scaffolds on Peripheral Interventions: Dreaming or Still Caution? |
William A. Gray |
Apr. 19. 24 |
| 215 |
Stentless TEVAR for Chronic Type IIIB Aortic Dissection |
Suk-Won Song |
Apr. 19. 24 |
| 214 |
Is TEVAR Safe and Durable in a Long-Term? |
Han Cheol Lee |
Apr. 19. 24 |
| 213 |
Is EVAR Safe and Durable in a Long-Term? |
Young-Guk Ko |
Apr. 19. 24 |
| 212 |
Renal Safety Issues in Dyslipidemia Treatment: Why is it Important? |
Duk-Woo Park |
Apr. 19. 24 |
